Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $36

Benzinga · 3d ago
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $38 to $36.